Format

Send to

Choose Destination
See comment in PubMed Commons below
Pharmacol Ther. 2001 Jan;89(1):17-27.

Antiretroviral therapeutic possibilities for human immunodeficiency virus/acquired immunodeficiency syndrome.

Author information

  • 1Laboratory of Clinical Pharmacology, Department of Psychiatry, New Clinics, University of Szeged, Medical Faculty, G.P.O. Box 427, H-6701 Szeged, Hungary. balint@nepsy.szote.u-szeged.hu

Abstract

In human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) illness, the reverse transcriptase and protease (PRT) enzymes of HIV are currently the targets of antiretroviral (ARV) therapy. Nucleoside analogues were the first group of ARV drugs that exerted antiviral activity in patients. More recently, PRT inhibitors have provided new approaches in the treatment of HIV infection and AIDS. Impressive clinical results have been obtained with combination therapies of three ARV drugs, including one PRT inhibitor. It is worth mentioning also that apart from these two main drug groups, there are many new compounds under development, including a vaccine(s) against HIV.

PMID:
11316511
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk